Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-05-03
2005-05-03
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S184100, C424S192100, C514S002600, C514S008100, C514S885000, C530S387100, C530S387300, C530S350000
Reexamination Certificate
active
06887471
ABSTRACT:
This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5580756 (1996-12-01), Linsley et al.
patent: 6641809 (2003-11-01), Linsley et al.
patent: 0 613 944 (1994-09-01), None
patent: WO 9300431 (1993-01-01), None
Sturmhoefel et al. Cancer Research 59:4964-4972 (1999).*
Kahau Cur. Opin. Immunol. 4:553-560 (1992).*
Blazar et al. J. Immunol. 167:3250-3259 (1996).*
Perrin et al. J. Neuroimmunol. 65:31-39 (1996).*
Yi-Qun et al. Intl. Immunol. 8:37-54 (1996).*
Coyle et al. Nature Immunol. 2:203-209 (2001).*
Skolnick et al. Trends in BioTech. 18:34-39 (2000).*
Ngo et al. in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Mere et al.(ED) Birkhauser Boston,MA, pp. 433, 492-495.*
Linsley et al. ,“Human B7-1 (CD80) and B7-2 (CD86) Bind with Similar Avidities by Distinct Kinetics to CD28 and CTLA-4 Receptors,”Immunity, 1994, 1:793-801, (Exhibit 65).
Peach et al., “Complementarity Determining Region 1 (CDR1)- CDR3-analogous in CTLA-4 and CD28 Determine the Binding to B7-1,” (1994) J. Exp. Med. 180:2049-2058. (Exhibit 66).
Fanslow, William C. et al., “Regulation of Alloreactivity in Vivo by IL-4 and the Soluble IL-4 Receptor”The Journal of Immunology, 1991, 147:535-40 (Exhibit 69).
Lenschow, Deborah J. et al., “Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg,”Science, 1992, 257: 789-92 (Exhibit 70).
Tan, Patrick et al., “Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymph cytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1,”Journal of Experimental Medicine, 1993, 177:165-73 (Exhibit 71).
Brummell, David A. et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues”Biochemistry, 1993, 32:1180-1187. (Ehibit 72). Weissenhorn, Winifred et al., “VH-Related Idiotopes Detected By Site-Directed Mutagenesis, A Study Induced by the Failure to find CD4 Anti-Idiotypic antibodies Mimicking the cellular receptor of HIV1,”Journal of Immunology, 1992, 149: 1237-1241 (Exhibit 73).
Janeway, “Approaching The Asymptote? Evolution And Revolution Immunology,”Cold Spring Harbor Symp. Quant. Biol., 1989, LIV:1-13. (Exhibit 4).
Shaw and Shimuzu, “Two Molecular Pathways Of Human T Cell,”Current Opinion in Immunology, 1988, 1:92-97. (Exhibit 5).
Hemler, “Adhesive Protein Receptors On Hematopoietic Cells,”Immunology Today, 1988, 9:109-113. (Exhibit 6).
Kakiuchi et al., “B Cells as Antigen-Presenting Cells: The Requirement for B Cell Activation,”J. Immunol., 1983, 131:109-114. (Exhibit 7).
Krieger et al., “Antigen Presentation Bye Splenic B Cells: Resting B Cells are Ineffective, Whereas Activated B Cells Are Effective Accesorry Cells For T Cells Responses,”J. Immunol., 1988, 135:2937-2945. (Exhibit 8).
Mckenzie, “Alloantogin Presentation By B Cells—Requirement for IL-I An IL-6,”J Immunol, 1988, 141:2907-2911. (Exhibit 9).
Hawrylowicz and Unaue, “Regulation of Antigen-Presentation-I IFN-γInduces Antigen- Presenting Properties On B Cells,”J. Immunol, 1988, 141:4803-4088. (Exhibit 10).
Springer et al., “The Lymphocyte Function-Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors Of The Immune System,”A. Rev. Immunol.1987, 5:223-252. (Exhibit 11).
Dinarello and Mier, “Current Concepts—Lymphokines,”New Engl. Journ. Med., 1987, 317:940-945. (Exhibit 12).
Weiss et al., “The Role Of The T3/Antigen Receptor Complex In T-Cell Activation,”Ann. Rev. Immunol, 1986, 4:593-619. (Exhibit 13).
McMichael, Ed., “Non-lineage, LFA-1 Family, And Leucocyte Common Antigens: New And Previously Defined Clusters,”Leukocyte Typing III, Oxford Univ. Press, Oxford UK, 1987. (Exhibit 14).
Moingeon et al., “CD2-Mediated Adhesion Facilitates T Lymphocyte Antigen Recognition Function,”Nature. 1988, 339:312-314, (Exhibit 15).
Magkoba et al., ICAM-1 A Ligand For LFA-1-Dependent Adhesion Of B, T, And Myeloid Cells,Nature, 1988, 331:86-88. (Exhibit 16).
Staunton et al., “Functional Cloning Of ICAM-2, A Cell Adhesion Ligand For LFA-1 Homologous To ICAM-1,”Nature, 1989, 339:61-64. (Exhibit 17).
Norment et al., “Cell-Cell Adhesion Mediated By CD8 And MHC Class I Molecules,”Nature, 1988, 336:79-81. (Exhibit 18).
Doyle and Strominger, “Interaction Between CD4 And Class II MHC Molecules Mediates Cell Adhesion,”Nature, 1987, 330:256-259. (Exhibit 19).
Stoolman, “Adhesion Molecules Controlling Lymphocyte Migration,”Cell, 1989, 56:907-910. (Exhibit 20).
Brescher and Cohn, “A Theory Of Self-Nonself Discrimination,”Science, 1970, 169:1042-1049. (Exhibit 21).
Freeman et al., “B7, A New Member of the Ig Superfamily With Unique Expression on Activated and Neoplastic B Cells,”J. Immunol., 1989, 143(8):2714-2722. (Exhibit 22).
Freedman et al., “B7, A B Cell-Restricted Antigen That Identifies Preactivated B Cells,”J. Immunol., 1987, 138:3260-3267. (Exhibit 23).
Clark et al., “Polypeptides On Human B Lymphocytes Associated With Cell Activation,”Human Immunol., 1986, 16:100-113. (Exhibit 24).
Yokochi et al., “B Lymphoblast Antigen (BB1-) Expressed On Epstein-Barr Virus-Activated B Cells Blasts, B Lymphblastoid Cell Lines, And Burkitt's Lymphomas,”J. Immunol., 1981, 128:823-827. (Exhibit 25).
Weiss, “Structure And Function Of The T Cell Antigen Receptor,”J. Clin Invest., 1990, 86:1015-1022. (Exhibit 26).
Allen, “Antigen Processing At The Molecular Level,”Immunol. Today, 1987, 8:270-273. (Exhibit 27).
Schwartz, “A Cell Culture Model For T Lymphocyte Clonal Anergy,”Science, 1990, 248:1349-1356. (Exhibit 28).
Weaver and Unanue, “The Costimultory Function Of Antigen-Presenting Cells,”Immunol Today, 1990, 11:49-55. (Exhibit 29).
Arrufo and Seed, “Molecular Cloning Of A CD28 CDNA By A High-Effeciency COS Cell Expression System,”Proc. Natl. Acad. Sci., 1987, 84:8573-8577. (Exhibit 30).
Damle et al., “Alloantigen-Specific Cytotoxic And Suppressor T Lymphocytes Are Derived From Phenotypically Distinct Precursors,”J. Immunol., 1983, 131:2296-2300. (Exhibit 31).
June et al., “T-Cell Proliferation involving The CD28 Pathway Is Associated With Cyclosporine-Resistant Interleukin 2 Gene Expression,”Mol. Cell. Biol., 1987, 7:4472-4481. (Exhibit 32).
Thompson et al., “CD28 Activation Pathway Regulates The Production Of Multiple T-Cell- Derived Lymphocytes/Cytokines,”Proc. Natl. Acad. Sci. 1989, 86:1333-1337. (Exhibit 33).
Linsten et al., “Regulationn Of Lymphokine Messenger RNA Stability Bye A Surface-Mediated T Cell Activation Pathway,”Science, 1989, 244:339-343. (Exhibit 34).
Damle et al., “Monoclonal Antibody Analysis Of Human T Lymphocyte Subpopulations exhibiting Autologous Mixed Lymphocyte Reaction,”Proc. Natl. Acad. Sci., 1981, 78:5096-5098. (Exhibit 35).
Lesslauer et al., “T90/44 (9.3 Antigen). A Cell Surface Molecule With A Function In Human T Cell Activation,”Eur. J. Immunol., 1986, 16:1289-1296. (Exhibit 36).
Linsley et al., “T-Cell Antigen CD28 Mediates Adhesion With B Cells By Interacting With Activation Antigen B/7BB-1,”Proc. Natl. Acad. Sci. USA, 1990, 87:5031-035. (Exhibit 37).
Linsley et al., “Binding Of The B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation And Interleukin 2 mRNA Accumulation,”J. Exp. Med., 1991, 173:721-730. (Exhibit 38).
Brady William
Damle Nitin K.
Ledbetter Jeffrey A.
Linsley Peter S.
Adriano Sarah B.
Bristol--Myers Squibb Company
Gambel Phillip
Sher Audrey F.
LandOfFree
Method to inhibit T cell interactions with soluble B7 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to inhibit T cell interactions with soluble B7, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to inhibit T cell interactions with soluble B7 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464182